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ABSTRACT
Voriconazole is a new antifungal agent that can be given orally and intravenously. It has proven efﬁcacy
for treating candidosis and invasive aspergillosis as well as other mould infections, such as those caused
by Fusarium and Scedosporium spp. The drug is generally well tolerated.
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INTRODUCTION
Voriconazole was discovered in the late 1980s.
The discovery process was started with the idea
of developing an antifungal agent with a spec-
trum of activity beyond that of ﬂuconazole. Like
ﬂuconazole, voriconazole belongs to the triazole
class of drugs (Fig. 1). It is relatively insoluble in
water, so the intravenous formulation contains
voriconazole in a sulphobutylether b-cyclodextrin
(SBECD) solute to allow for parenteral adminis-
tration.
The clinical development programme included
the largest-ever randomised controlled trial in the
treatment of invasive aspergillosis. The ﬁndings
of this trial demonstrate the signiﬁcantly superior
efﬁcacy of a clinical regimen that starts with
voriconazole, over standard therapy starting with
amphotericin B deoxycholate.
MECHANISM OF ACTION
Voriconazole selectively inhibits the fungal cyto-
chrome P450-dependent enzyme 14a-sterol deme-
thylase, thereby interrupting an essential step in
ergosterol biosynthesis (Fig. 2). The drug is about
250-fold more active against the fungal demethy-
lase enzyme than against mammalian P450-
dependent steroid hormone biosynthesis
[1].
SPECTRUM OF ACTIVITY
Voriconazole exhibits broad-spectrum activity at
concentrations of £ 1 mg ⁄L against the more
common fungal pathogens such as Candida spp.
(including ﬂuconazole-resistant C. krusei) and
is fungicidal to Aspergillus spp. as well as to
Scedosporium and Fusarium spp. and certain
other moulds (Fig. 3). The drug also exhibits
good activity against less-common clinical iso-
lates, including Acremonium, Alternaria, Bipolaris,
Cladophialophora, Curvularia and Chrysosporium spp.
[2], as well as the dimorphic fungi Histoplasma
capsulatum, Blastomyces dermatitidis and Coccidio-
ides immitis [3]. Voriconazole has little activity
Fig. 1. Structural relationship between voriconazole and
ﬂuconazole.
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against Sporothrix schenckii [4] and the zygomyc-
etes, such as Mucor, Rhizopus and Absidia spp.
[2].
Correlating in-vitro activity with clinical out-
come remains elusive because host factors other
than pathogen susceptibility are involved. Break-
points for voriconazole have yet to be estab-
lished.
PHARMACOKINETIC PROPERTIES
The pharmacokinetics of voriconazole are non-
linear, which leads to a greater than propor-
tional increase in exposure with increasing dose.
For instance, increasing the oral dose from
200 mg to 300 mg twice daily leads to a 2.5-
fold increase in the area under the plasma
Fig. 2. Mode of action of antifungal
agents.
Fungus AMB FCZ ICZ VCZ PCZ CAN
Candida albicans
Candida tropicalis
Candida parapsilosis
Candida krusei
Candida glabrata
Cryptococcus neoformans
Histoplasma capsulatum
Blastomyces dermatitidis
Coccidiodes immitis
Paracoccidiodes brasiliensis
Aspergillus fumigatus
Zygomycetes
Fusarium solani
Scedosporium apiospermum
?
?
?
AMB  amphotericin B
FCZ   fluconazole
ICZ    itraconazole
VCZ  voriconazole
PCZ   posaconazole
CAN  candins   
Fig. 3. Comparative spectrum of
activity in-vitro of antifungal agents.
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concentration-time curve (AUC). While there is
a low intrapatient variability in plasma concen-
trations, the interindividual variability of voric-
onazole pharmacokinetics is high. Population
pharmacokinetic data from therapeutic trials
have revealed no association between plasma
concentration and clinical outcome. The terminal
half-life of voriconazole is dose dependent
and is not predictive of its accumulation or
elimination.
Absorption
Voriconazole is rapidly and almost completely
absorbed following oral administration, with
maximum plasma concentrations being achieved
1–2 h after dosing. The oral bioavailability of
voriconazole is estimated to be 96%, which may
permit switching between intravenous (IV) and
oral formulations when clinically appropriate.
Absorption is not affected by changes in gastric
pH. As the presence of high-fat food affects
voriconazole absorption, oral voriconazole should
not be taken within 1 h of a meal.
Distribution
The volume of distribution at steady state for
voriconazole is estimated to be 4.6 L ⁄kg, suggest-
ing extensive distribution into tissues. Plasma
protein binding is estimated to be 58% and is
independent of dose or plasma concentrations.
The drug is also detectable in cerebrospinal ﬂuid
samples (data on ﬁle).
Metabolism
In-vitro studies showed that voriconazole is
metabolised by the hepatic cytochrome P450
isoenzymes, CYP2C19, CYP2C9 and CYP3A4.
The isoenzyme CYP2C19 exhibits genetic poly-
morphism with 15–20% of Asian populations
being poor ⁄ slow metabolisers [5], whereas the
prevalence is much lower (3–5%) amongst Cau-
casians and Blacks. Studies conducted in Cauca-
sian and Japanese healthy subjects have shown
that poor metabolisers have, on average, four-
fold higher voriconazole AUC than homozy-
gous extensive metabolisers, while the AUC of
heterozygous extensive metabolisers is two-fold
higher than that of homozygous extensive metab-
olisers.
The major metabolite of voriconazole is the
N-oxide, which has negligible antifungal activity
and accounts for 72% of the circulating radio-
labelled metabolites in plasma. In all, metabolism
produces at least eight compounds without clin-
ically signiﬁcant antifungal activity.
Excretion
Approximately 80% of a single, radiolabelled
dose of voriconazole is excreted in the urine,
almost completely as metabolites. Less than 2% of
the dose is excreted in the urine as unchanged
drug. The majority (> 94%) of the total radioac-
tivity is excreted in the ﬁrst 96 h after both oral
and intravenous dosing. Approximately 20% of
the drug is excreted in the faeces.
CLINICAL STUDIES OF EFFICACY
The strategy of evaluating the efﬁcacy and safety
of voriconazole for treating aspergillosis and can-
didiasis was rewarded by the drug being licensed
for these indications. In addition, the results
obtained from a study of documented invasive
fungal infections with no approved antifungal
therapy, or infections that were refractory to
approved therapy (due to treatment failure or
intolerance of therapy), and from compassionate
use programmes indicate that voriconazole is an
important therapeutic option for treating predom-
inantly fatal infections caused by other less
common moulds, including Fusarium and Scedos-
porium spp.
Aspergillosis
An open, noncomparative study of 116 patients
with invasive aspergillosis resulted in an overall
efﬁcacy of 48% (56 complete ⁄partial responses)
[6]. Fifty (60%) of the 84 patients with pulmonary
infection responded well to treatment with voric-
onazole, 6 mg ⁄kg twice a day on the ﬁrst day,
followed by 3 mg ⁄kg twice daily for 6–27 days
and 200 mg twice daily, given orally for up to
24 weeks. The results obtained in this population,
which comprised newly diagnosed as well as
previously treated patients, compared favourably
to those achieved previously with other drugs
[7–11]. Admittedly, differences in patient and
disease characteristics make comparisons difﬁcult,
but the response rate of 42% observed in the 19
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patients with aspergillosis of the central nervous
system is promising.
The results of this noncomparative study were
conﬁrmed in the largest randomised controlled
trial ever undertaken for any antifungal agent in
the primary treatment of invasive aspergillosis
[12]. Ninety-ﬁve centres world-wide treated 391
immunocompromised patients with either voric-
onazole (given as two 6 mg ⁄ kg infusions 12 h
apart on the ﬁrst day, followed by 4 mg ⁄ kg every
12 h for at least 7 days, after which treatment
could be continued orally 200 mg every 12 h) or
1–1.5 mg ⁄ kg ⁄day amphotericin B deoxycholate
given intravenously. The protocol-deﬁned treat-
ment period was 12 weeks. At the investigators’
discretion, initial randomised therapy could be
switched to any other licensed therapy (lipid
formulations of amphotericin B or itraconazole)
when initial treatment was poorly tolerated or
there was no response. Patients judged by an
independent, blinded panel to have insufﬁcient
evidence to conﬁrm their initial diagnosis of
aspergillosis were excluded from the ‘modiﬁed
intent-to-treat’ (MITT) population. These patients
(50 randomised to voriconazole and 52 to amph-
otericin B) were not evaluated for efﬁcacy. Hence,
277 patients were included in the MITT popula-
tion and were evaluated for efﬁcacy.
A satisfactory response (complete or partial
resolution of all attributable symptoms and signs
and of radiographic or bronchoscopic abnormal-
ities present at baseline) was recorded for 76 (53%)
of the 144 patients treated with voriconazole but
only for 42 (32%) of the 133 patients treated with
amphotericin B (P ¼ 0.0001; Fig. 4). Response
rates favoured voriconazole irrespective of whe-
ther the diagnosis was considered proven or
probable, whether the infection was disseminated
or pulmonary, and regardless of the underlying
condition, or presence of neutropenia. The
12-week survival rate was also higher for the
voriconazole group (71%, compared with 58% for
amphotericin B group; P ¼ 0.02). More than twice
as many patients (29%) randomised to amphoter-
icin B died from invasive aspergillosis as those
randomised to voriconazole (13%).
Treatment with voriconazole was sustained
longer, with a median duration of 77 days (range
2–84 days), compared with 10 days (range
1–84 days) for patients receiving amphotericin
B. Fifty-two (36%) patients who started in
the voriconazole arm were switched to other
licensed therapy. By contrast, and not unexpect-
edly, 107 (80%) of patients who started in the
amphotericin B arm were switched to other
licensed therapy.
Overall, fewer adverse events were reported for
patients receiving voriconazole, despite the longer
median duration of therapy, compared with
amphotericin B. Although approximately 10 times
more voriconazole patients (87, 45%) than amph-
otericin B patients (8, 4%) reported transient
visual disturbances (blurred vision, altered visual
or colour perception, or photophobia, which all
resolved spontaneously), the converse was true of
chills and fever, which affected 46 (25%) of those
given amphotericin B, compared with six (3%) of
those treated with voriconazole. Eighteen patients
(9%) receiving voriconazole had an adverse event
of hypokalemia, compared with 47 (25%) on
amphotericin B. Strikingly, seven patients (4%)
treated with voriconazole were recorded as hav-
ing acute kidney failure, while this was consid-
ered an adverse event for 89 patients (48%) given
amphotericin B ⁄ other licensed therapy. Serious
side-effects also affected more patients treated
with amphotericin (45 patients; 24%) than with
voriconazole (26 patients; 13%). Other adverse
events were infrequent and affected similar num-
bers in both groups.
Fig. 4. Efﬁcacy of voriconazole compared with ampho-
tericin B for treating invasive aspergillosis.
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Candidosis
Voriconazole has been shown to be as effective as
ﬂuconazole for treating oesophageal candidiasis,
achieving a cure rate among endoscopy-con-
ﬁrmed cases of 113 of 115 patients (98.3%),
compared with 134 of 141 (95.0%) on ﬂuconazole
[13]. Both drugs were generally well tolerated,
although 36 (18%) of the 159 patients treated with
voriconazole experienced mild reversible visual
abnormalities. Indeed, visual disturbance seems
characteristic of voriconazole, but studies have
shown no impact of long-term use on eye struc-
ture or function. This side-effect may only prove
important to ambulatory patients who should not
drive or use machinery while affected [14].
Scedosporium and Fusarium infections
Sixteen of 28 patients treated with voriconazole
for infections caused by S. apiospermum success-
fully responded, as did two of seven patients
treated for S. proliﬁcans infections (data on ﬁle).
Seven of 17 patients were treated successfully
with voriconazole for infections due to Fusarium
spp. Most of the patients had either been intoler-
ant of, or refractory to, prior antifungal therapy.
In particular, the efﬁcacy of voriconazole against
potentially life-threatening infections by Scedospo-
rium spp. is striking.
Empirical therapy
Voriconazole and liposomal amphotericin B
(AmBisome) were also shown to be similarly
effective for empiric therapy [15], although voric-
onazole failed to meet the statistical endpoint of
noninferiority to the comparator across all com-
ponents of the study composite endpoint. Overall
response rates were low, being 108 of 415 (26%)
for voriconazole and 131 of 422 (31%) for
AmBisome, and resolution of fever during
neutropenia in only 137 (33%) and 152 (36%) of
episodes, respectively. Nonetheless, the survival
rates were 87% and 90%, respectively. The
number of breakthrough fungal infections in
patients treated empirically with voriconazole
was 8 (2%), compared with 21 (5%) for those on
liposomal amphotericin B. There were fewer
severe infusion-related reactions related to vorico-
nazole and less nephrotoxicity than was encoun-
tered with liposomal amphotericin B, although
transient visual changes affected almost a quarter
of those treated with voriconazole.
Such studies are valuable for assessing the
safety of the drugs used, but are difﬁcult to assess
in terms of efﬁcacy since most patients do not have
a fungal disease. Moreover, some of the break-
through infections may only represent the further
manifestation of an infection that was already
present, but undetected, at the start of empiric
therapy. The cases of fungal infection that occur
can lead to a better understanding of the drug’s
potential but this necessitates subgroup analysis
and essentially results in a series of cases, which,
as such, has limited statistical power. It also brings
into question the rationale for using fever to guide
antifungal therapy decision-making.
Experience in paediatric patients
Sixty-one paediatric patients aged 9 months up to
15 years who had deﬁnite or probable invasive
fungal infections were treated with voriconazole.
This population included 34 patients aged from 2
to < 12 years old and 20 patients aged 12 to
15 years. The majority (57 ⁄ 61) had failed previous
antifungal therapies. Therapeutic studies included
ﬁve patients aged 12 to 15 years, the remaining
patients received voriconazole in the compassio-
nate use programmes. Underlying diseases in
these patients included haematological malignan-
cies and aplastic anaemia (27 patients) and
chronic granulomatous disease (14 patients). The
most commonly treated fungal infection was
aspergillosis (43 ⁄ 61; 70%).
Miscellaneous infections
Invasive aspergillosis involving the central ner-
vous system is known to have a dismal outcome. A
patient with acute leukaemia who developed a
cerebral abscess due to Aspergillus has been suc-
cessfully treated [16]. In the study of Denning et al.
there were 19 cases of cerebral brain invasive
aspergillosis, of which ﬁve were proven. Three
patients (16%) had a partial response and ﬁve
achieved a stable response [6]. In a retrospective
study of eight consecutive cases of brain invasive
aspergillosis admitted to a single intensive-care
unit between 1990 and 1999, all ﬁve treated before
1997 died [17]. Of the three survivors, two had
been treated with voriconazole and the other with
itraconazole, as had one of those who had died.
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More recently, in a study of refractory infections,
four of 12 patient (33%) with cerebral aspergillosis
had successful outcomes at the end of treatment
with voriconazole [18]. A case of brain abscess due
to Pseudallescheria boydii was successfully treated
with surgical drainage and systemic voriconazole
[19], as was an unusual case of chronic meningitis
due to the same fungus [20]. Although far from
conclusive, these results offer hope of successful
treatment for a hitherto intractable disease.
OFFICIAL LABELLING
AND INDICATIONS
In Europe, voriconazole is indicated for the treat-
ment of invasive aspergillosis, ﬂuconazole-resist-
ant serious invasive candida infections (including
C. krusei), and serious fungal infections caused by
Scedosporium and Fusarium spp. It is recommended
that voriconazole should be administered primar-
ily to immunocompromised patients with pro-
gressive, possibly life-threatening infections. In
the US, voriconazole is indicated for the treatment
of invasive aspergillosis and serious fungal infec-
tions caused by S. apiospermum and Fusarium spp.,
including F. solani, in patients intolerant of, or
refractory to, other therapy.
DRUG ADMINISTRATION
An intravenous loading dose of 6 mg ⁄ kg at
12-hourly intervals should be administered on
day 1, followed by a maintenance dose of 4 mg ⁄ kg
12-hourly. Voriconazole should be administered
at a maximum rate of 3 mg ⁄ kg per hour over
1–2 h. Maintenance therapy can be switched to
oral form at a dose of 200 mg 12-hourly (for
patients ‡ 40 kg) or 100 mg 12-hourly (for patients
< 40 kg). If therapy is initiated with the oral form,
a loading dose of 400 mg 12-hourly (200 mg
12-hourly for patients < 40 kg) should be adminis-
tered on day 1. Administration of a loading dose
on day 1 results in peak plasma concentrations
close to steady state within 24 h. Treatment
duration depends on the patient’s clinical and
mycological response. Oral voriconazole should
be taken at least 1 h before or after a meal.
Special patient groups
No dosage adjustment is necessary based on
gender or age ‡ 12 years; however, a maintenance
dose of 4 mg ⁄ kg IV (or the closest equivalent in
oral form) every 12 h is recommended for chil-
dren aged between 2 and < 12 years of age.
Patients with mild to moderate hepatic cirrho-
sis (Child–Pugh Class A or B) should receive the
standard loading dose of voriconazole but the
maintenance dose should be halved [21].
Patients with moderate to severe renal dys-
function (creatinine clearance < 50 mL ⁄min) may
experience accumulation of the vehicle SBECD
when given voriconazole intravenously. Oral
voriconazole should be administered to these
patients, unless the beneﬁt of IV therapy out-
weighs the risk. Serum creatinine levels should be
closely monitored in these patients and considera-
tion given to changing to oral therapy.
INTERACTIONS
Effects of other medicinal products
on voriconazole
Voriconazole is metabolized by cytochrome P450
isoenzymes, CYP2C19, CYP2C9 and CYP3A4.
Inducers or inhibitors of these isoenzymes may
increase or decrease voriconazole plasma concen-
trations, respectively.
Rifampicin (a CYP450 inducer; 600 mg once
daily) decreased the Cmax (maximum plasma
concentration) and AUCs (area under the plasma
concentration-time curve within a dose interval)
of voriconazole by 93% and 96%, respectively
[22]. Coadministration of voriconazole and rif-
ampicin is contraindicated. Carbamazepine and
phenobarbital are likely to signiﬁcantly decrease
plasma voriconazole concentrations and co-
administrationwithvoriconazoleiscontraindicated.
Cimetidine increased voriconazole Cmax and
AUCs by 18% and 23%, respectively. No dosage
adjustment of voriconazole is recommended.
Ranitidine had no signiﬁcant effect on voricon-
azole Cmax or AUCs.
The macrolide antibiotics erythromycin and
azithromycin had no signiﬁcant effect on voric-
onazole Cmax and AUCs.
Effects of voriconazole on other medicinal
products
Voriconazole inhibits the activity of cytochrome
P450 isoenzymes, CYP2C19, CYP2C9 and CYP3-
A4. Thus, there is potential for voriconazole to
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increase the plasma levels of substances metabo-
lized by these CYP450 isoenzymes.
Coadministration of voriconazole with terfena-
dine, astemizole, cisapride, pimozide or quinidine
is contraindicated, because increased plasma
concentrations of these medicinal products can
lead to QTc prolongation and rare occurrences of
torsades de pointes.
Voriconazole increased sirolimus (2 mg single
dose) Cmax and AUCs by 556% and 1014%,
respectively. Coadministration of voriconazole
and sirolimus is contraindicated.
Voriconazole may increase the plasma concen-
trations of ergot alkaloids (ergotamine and
dihydroergotamine) and lead to ergotism. Coad-
ministration of voriconazole with ergot alkaloids
is contraindicated.
In stable renal transplant recipients, voriconaz-
ole increased cyclosporine Cmax and AUCs by at
least 13% and 70%, respectively. When initiating
voriconazole in patients already receiving
cyclosporine, it is recommended that the cyclosp-
orine dose be halved and that the cyclosporine
level be carefully monitored [23]. Increased
cyclosporine levels have been associated with
nephrotoxicity. When voriconazole is discontin-
ued, cyclosporine levels must be carefully mon-
itored and the dose increased as necessary.
Voriconazole increased tacrolimus Cmax and
AUCs by 117% and 221%, respectively. When
initiating voriconazole in patients already receiv-
ing tacrolimus, it is recommended that the tacr-
olimus dose be reduced to a third of the original
dose and that the tacrolimus level be carefully
monitored [24,25]. Increased tacrolimus levels
have been associated with nephrotoxicity. When
voriconazole is discontinued, tacrolimus levels
must be carefully monitored and the dose
increased as necessary.
Coadministration of voriconazole with warfarin
(an anticoagulant) increased the maximum pro-
thrombin time by 93%. Close monitoring of pro-
thrombin time is recommended if warfarin and
voriconazole are coadministered [26]. Voriconaz-
ole may increase the plasma concentrations of
coumarins, such as phenprocoumon and acen-
ocoumarol, and therefore may cause an increase in
prothrombin time. If patients receiving coumarin
preparations are treated simultaneously with vor-
iconazole, the prothrombin time should be monit-
ored at close intervals and the dosage of
anticoagulants should be adjusted accordingly.
Voriconazole may increase the plasma levels of
sulphonylureas, such as tolbutamide, glipizide
and glyburide, and therefore cause hypoglycae-
mia. Careful monitoring of blood glucose is
recommended during coadministration.
Voriconazole has been shown to inhibit lovast-
atin metabolism in vitro in human liver micro-
somes, therefore voriconazole is likely to increase
plasma levels of statins that are metabolised by
CYP3A4. It is recommended that dose adjustment
of the statin be considered during coadministra-
tion. Increased statin levels have been associated
with rhabdomyolysis.
Althoughnotstudiedclinically,voriconazolehas
been shown to inhibit the metabolism of midazo-
lam (a benzodiazepine) in vitro (human livermicro-
somes).Voriconazole is likely, therefore, to increase
the plasma levels of benzodiazepines that are
metabolized by CYP3A4 (e.g. midazolam and tria-
zolam) and lead to a prolonged sedative effect. It is
recommended that dose adjustment of the benzo-
diazepine be considered during coadministration.
Voriconazole may increase the plasma levels of
the vinca alkaloids (e.g. vincristine and vinblas-
tine) and lead to neurotoxicity.
Voriconazole increased Cmax and AUCs of pre-
dnisolone (60 mg single dose) by 11% and 34%,
respectively. No dosage adjustment is recommen-
ded [27].
Voriconazole had no signiﬁcant effect on Cmax
and AUCs of digoxin (0.25 mg once daily) [28] or
mycophenolic acid (a UDP-glucuronyl transferase
substrate; 1 g single dose) [29].
Two-way interactions
Phenytoin (CYP2C9 substrate and potent CYP450
inducer)
Concomitant use of voriconazole and pheny-
toin should be avoided unless the beneﬁt out-
weighs the risk. Careful monitoring of phenytoin
plasma levels is recommended when phenytoin is
coadministered with voriconazole. Phenytoin may
be coadministered with voriconazole if the main-
tenance dose of voriconazole is increased to
5 mg ⁄ kg intravenously twice daily or from
200 mg to 400 mg orally, twice daily (100 mg to
200 mg orally, twice daily in patients < 40 kg) [30].
Rifabutin (CYP450 inducer)
Concomitant use of voriconazole and rifabutin
should be avoided unless the beneﬁt outweighs the
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risk. If rifabutin coadministration with voriconaz-
ole is justiﬁed then the maintenance dose of
voriconazole may be increased to 5 mg ⁄ kg intra-
venously twice daily or from 200 mg to 350 mg
orally, twice daily (100 mg to 200 mg orally, twice
daily in patients less than 40 kg). Careful monitor-
ing of full blood counts and adverse events to ri-
fabutin (e.g. uveitis) is recommended when
rifabutin is coadministered with voriconazole [22].
Omeprazole (CYP2C19 inhibitor; CYP2C19 and
CYP3A4 substrate)
Omeprazole (40 mg once daily) increased voric-
onazole Cmax and AUCs by 15% and 41%,
respectively. No dosage adjustment of voriconaz-
ole is recommended. Voriconazole increased
omeprazole Cmax and AUCs by 116% and 280%,
respectively. When initiating voriconazole in
patients already receiving omeprazole, it is
recommended that the omeprazole dose be
halved [31,32]. The metabolism of other proton
pump inhibitors that are CYP2C19 substrates may
also be inhibited by voriconazole.
Indinavir (CYP3A4 inhibitor and substrate)
Indinavir (800 mg three times daily) had no
signiﬁcant effect on voriconazole Cmax, Cmin and
AUCs. Voriconazole did not have a signiﬁcant
effect on Cmax and AUCs of indinavir (800 mg
three times daily) [33].
Other HIV protease inhibitors (CYP3A4 inhibitors)
In-vitro studies suggest that voriconazole may
inhibit the metabolism of human immunode-
ﬁciency virus (HIV) protease inhibitors (e.g.
saquinavir, amprenavir and nelﬁnavir). In-vitro
studies also show that the metabolism of voric-
onazole may be inhibited by HIV protease
inhibitors. Results of the combination of voric-
onazole with other HIV protease inhibitors,
however, cannot be predicted in humans only
from in-vitro studies. Patients should be care-
fully monitored for any occurrence of drug
toxicity and ⁄ or loss of efﬁcacy during the
coadministration of voriconazole and HIV pro-
tease inhibitors.
Non-nucleoside reverse transcriptase inhibitors
(NNRTI) (CYP3A4 substrates, inhibitors or CYP450
inducers)
In-vitro studies show that the metabolism of
voriconazole may be inhibited by delavirdine
and efavirenz. Although not studied, the metabo-
lism of voriconazole may be induced by efavirenz
and nevirapine. Voriconazole may also inhibit the
metabolism of NNRTIs. Due to the lack of in-vivo
studies, patients should be carefully monitored
for any occurrence of drug toxicity and ⁄ or lack of
efﬁcacy during the coadministration of voricon-
azole and NNRTIs.
ADVERSE EXPERIENCES
Data on the safety of voriconazole is derived from
2000 subjects, of whom 1493 were patients treated
in therapeutic trials [34]. The most commonly
reported adverse events are displayed in Table 1.
Visual disturbances, dermatological reactions and
liver function test abnormalities were common.
Age, race and gender had no inﬂuence on the
nature or frequency of adverse events.
Visual disturbances
In clinical trials, approximately 30% of subjects
experienced altered ⁄ enhanced visual perception,
blurred vision, colour vision change, or photo-
Table 1. Treatment-emergent adverse eventsa reported by
at least 1% of patients in voriconazole therapeutic studies,
by body system (n ¼ 1493)
Special senses
Abnormal vision (20.6%); Photophobia (2.4%);
Chromatopsia (1.3%)
Body as a whole
Fever (6.2%); Chills (4.1%); Headache (3.2%);
Abdominal pain (1.7%)
Cardiovascular system
Tachycardia (2.5%); Hypertension (1.9%); Hypotension
(1.7%); Vasodilatation (1.5%)
Digestive system
Nausea (5.9%); Vomiting (4.8%); Liver function tests
abnormal (2.7%); Diarrhoea (1.1%); Cholestatic jaundice
(1.1%); Dry mouth (1.0%)
Metabolic and nutritional systems
Alkaline phosphatase increased (3.6%); Hepatic enzymes
increased (1.9%); ASAT (SGOT) increased (1.9%); ALAT
(SGPT) increased
(1.8%); Hypokalaemia (1.6%); Peripheral oedema (1.1%);
Hypomagnesaemia (1.1%)
Nervous system
Hallucinations (2.5%); Dizziness (1.3%)
Skin and appendages
Rash (5.8%); Pruritus (1.1%); Maculopapular rash (1.1%)
aEvents recorded as possibly related to therapy or of
unknown causality.
ASAT, aspartate aminotransferase; ALAT, alanine trans-
aminase.
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phobia. The visual disturbances usually occurred
around half an hour after administration of
voriconazole, usually spontaneously resolved
within an hour, and were commonest during
the ﬁrst week of treatment [14]. The reactions are
generally mild, seldom necessitating stopping
treatment, are transient and completely reversi-
ble, and do not appear to lead to long-term
sequelae. The mechanism behind these reactions
is unknown. Visual disturbances may be associ-
ated with higher plasma concentrations and ⁄ or
doses.
Dermatological reactions
Mild or moderate dermatological reactions tend
to affect patients with serious underlying diseases
who were receiving various other medications.
Serious cutaneous reactions, including Stevens–
Johnson syndrome, toxic epidermal necrolysis, and
erythema multiforme, are rare. Photosensitivity
reactions have been reported, especially during
long-term treatment.
Liver function tests
Liver function test abnormalities were seen in
13.4% of trial subjects, and may be associated
with higher plasma concentrations or dosages of
voriconazole. Liver function test abnormalities
resolved either without any alterations in dosage
or after dose adjustment or stopping treatment
(seldom required). Voriconazole has been infre-
quently associated with cases of serious hepatic
toxicity in patients with other serious underlying
conditions. This includes cases of jaundice, and
rare cases of hepatitis and hepatic failure leading
to death.
Infusion-related reactions
As with other drugs, anaphylactic reactions such
as ﬂushing, fever, sweating and tachycardia have
occurred rarely, immediately upon starting an
infusion of voriconazole.
THE PLACE OF VORICONAZOLE
Compared with a decade ago, we seem to be
spoiled for choice when it comes to antifungal
drugs, but appearances can be deceptive, especi-
ally when considering the treatment of invasive
fungal infection. Essentially, there are three clas-
ses of drugs—the polyenes (amphotericin B in its
various forms), the triazoles (ﬂuconazole, itracon-
azole and voriconazole), and the candins (caspo-
fungin)—and two strategies available to us, one
that relies entirely on intravenous therapy and the
other that aims to switch from parenteral to oral
treatment. Each class of drug can be employed
parenterally but only the azoles can be used to
complete the second strategy.
The frustration at not being able to identify
patients with mould infections at an early stage
may drive clinicians to resort to giving voricon-
azole for prophylaxis, even though there are no
clinical data available on the use of the drug in
this setting. Early detection, resulting in early
initiation of treatment, is crucial in the manage-
ment of many mould infections, and is likely to
remain an area of focus in the future. The true
value of voriconazole may only become apparent
once management strategies achieve a better
balance between diagnosis and treatment, and
risks are better deﬁned so that patients who need
therapy are treated optimally, and those who do
not need it are identiﬁed and spared unnecessary
exposure to antifungal agents.
Voriconazole represents a clear advance in the
treatment of invasive aspergillosis, with proven
superiority over amphotericin B, in terms of both
efﬁcacy and patient survival. The study compar-
ing voriconazole and amphotericin B for primary
therapy of invasive aspergillosis, which is the
largest therapeutic study undertaken of this
disease, also indicated that voriconazole is
better tolerated than amphotericin B [12]. Des-
pite the median duration of therapy being longer
in patients randomised to voriconazole than in
those randomised to amphotericin B, there
were still signiﬁcantly fewer treatment-related
adverse events in the voriconazole arm (343,
compared with 421 in the amphotericin B arm;
P ¼ 0.02).
The population included in the invasive asper-
gillosis study [12] included severely ill patients.
Due to their underlying conditions, such patients
are liable to receive numerous concomitant med-
ications, and are prone to drug–drug interactions
and adverse events related to their antifungal
therapy. Consequently, this population is difﬁcult
to treat, and previous clinical studies in these
patients have been almost exclusively limited to
trials using amphotericin B. The availability of oral
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and intravenous formulations of voriconazole
means that the therapeutic options available
for the most seriously ill patients are increased.
Earlier studies of azole therapy for invasive
aspergillosis, using itraconazole, could not include
the most severely ill patients, due to the lack of an
IV formulation (oral dosing is not possible for
the most ill). In one such study, 30 (39%) of 76
evaluable patients had a complete or partial
response at the end of treatment with oral itrac-
onazole, 600 mg ⁄day for 4 days, followed by
400 mg ⁄day [35]. Even though this study cannot
be compared directly with the voriconazole study
[12], the higher proportion of patients with a
satisfactory response rate to voriconazole (76 ⁄ 144
patients, 53%) is particularly striking, considering
the severely ill patient population enrolled in the
latter study. Although an intravenous formulation
of itraconazole has now been developed, its use to
treat invasive aspergillosis has only been evalu-
ated in a relatively small-scale (31 patients),
noncomparative study [36,37].
In addition to its efﬁcacy in the treatment of
infections caused by Aspergillus [6,12] and Candida
spp. [13], voriconazole also constitutes a poten-
tially life-saving therapy for patients with infec-
tions caused by less-common fungal pathogens.
A recent study has demonstrated the efﬁcacy of
voriconazole in treating patients with documen-
ted invasive fungal infections with no approved
antifungal therapy or infections that were refract-
ory to approved therapy (due to treatment failure
or intolerance of therapy) [18]. Despite the seri-
ously ill patient population, and the high risk of
treatment failure (approximately 75% of the 301
patients evaluated for efﬁcacy had failed to
respond to other antifungal agents), there was
an overall survival rate of 66% 90 days after
starting voriconazole therapy, and a satisfactory
global response rate of 50%. Efﬁcacy rates by
pathogen in this study included 62 ⁄ 142 (43.7%)
and 50 ⁄ 87 (57.5%) for refractory aspergillosis and
candidiasis, respectively, 9 ⁄ 10 (90%) for penicil-
liosis, 5 ⁄ 11 (45%) for fusariosis, and 3 ⁄ 10 (30%)
for scedosporiosis. Again, voriconazole was
acceptably tolerated, despite the diverse nature
of the patients studied and their severe illnesses.
Although visual events and elevated liver func-
tion test results were observed, if monitored
closely, these ﬁndings rarely developed into
serious adverse events, even in this complex
patient group.
Voriconazole is clearly a valuable and import-
ant addition to the limited armamentarium cur-
rently at our disposal, and the information we
now have about this agent is sufﬁciently compel-
ling for it to earn a place in any antifungal
management strategy.
REFERENCES
1. Ghannoum MA, Kuhn DM. Voriconazole—better chances
for patients with invasive mycoses. Eur J Med Res 2002; 7:
242–56.
2. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro
evaluation of voriconazole against clinical isolates of
yeasts, moulds and dermatophytes in comparison with
itraconazole, ketoconazole, amphotericin B and griseoful-
vin. Mycoses 1998; 41: 309–19.
3. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW,
McGinnis MR. In vitro activities of voriconazole, itracon-
azole, and amphotericin B against Blastomyces dermatitidis,
Coccidioides immitis, and Histoplasma capsulatum. Antimicrob
Agents Chemother 2000; 44: 1734–6.
4. McGinnis MR, Nordoff N, Li RK, Pasarell L, Warnock DW.
Sporothrix schenckii sensitivity to voriconazole, itraconazole
and amphotericin B. Med Mycol 2001; 39: 369–71.
5. Balian JD, Sukhova N, Harris JW et al. The hydroxylation
of omeprazole correlates with S-mephenytoin metabo-
lism: a population study. Clin Pharmacol Ther 1995; 57:
662–9.
6. Denning DW, Ribaud P, Milpied N et al. Efﬁcacy and
safety of voriconazole in the treatment of acute invasive
aspergillosis. Clin Infect Dis 2002; 34: 563–71.
7. Chopra R, Fielding A, Goldstone AH. Successful treatment
of fungal infections in neutropenic patients with liposomal
amphotericin (AmBisome)–a report on 40 cases from a
single centre. Leuk Lymphoma 1992; 7 (Suppl.): 73–7.
8. Denning DW, Tucker RM, Hanson LH, Stevens DA.
Treatment of invasive aspergillosis with itraconazole. Am J
Med 1989; 86: 791–800.
9. Mehta J, Kelsey S, Chu P et al. Amphotericin B lipid
complex (ABLC) for the treatment of conﬁrmed or pre-
sumed fungal infections in immunocompromised patients
with hematologic malignancies. Bone Marrow Transplant
1997; 20: 39–43.
10. Oppenheim BA, Herbrecht R, Kusne S. The safety and
efﬁcacy of amphotericin B colloidal dispersion in the
treatment of invasive mycoses. Clin Infect Dis 1995; 21:
1145–53.
11. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid for-
mulations of amphotericin B: clinical efﬁcacy and toxici-
ties. Clin Infect Dis 1998; 27: 603–18.
12. Herbrecht R, Denning DW, Patterson TF et al. Voriconaz-
ole versus amphotericin B for primary therapy of invasive
aspergillosis. N Engl J Med 2002; 347: 408–15.
13. Ally R, Schu¨rmann D, Kreisel W et al. A randomized,
double-blind, double-dummy, multicenter trial of voric-
onazole and ﬂuconazole in the treatment of esophageal
candidiasis in immunocompromised patients. Clin Infect
Dis 2001; 33: 1447–54.
14. Tomaszewski K, Purkins L. Visual effects with voricon-
azole [Abstract A-639]. In: Program and Abstracts of the 41st
116 Clinical Microbiology and Infection, Volume 10 Supplement 1, 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 1), 107–117
Interscience Conference on Antimicrobial Agents and Chemo-
therapy. Chicago, IL: American Society of Microbiology,
2001; 20.
15. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole com-
pared with liposomal amphotericin B for empirical anti-
fungal therapy in patients with neutropenia and persistent
fever. N Engl J Med 2002; 346: 225–34.
16. Schwartz S, Milatovic D, Thiel E. Successful treatment of
cerebral aspergillosis with a novel triazole (voriconazole)
in a patient with acute leukaemia. Br J Haematol 1997; 97:
663–5.
17. Tattevin P, Bruneel F, Lellouche F et al. Brain aspergillosis:
Impact of azole therapy [Abstract M-869]. In: Program and
Abstracts of the 42nd Interscience Conference on Antimicrobial
Agents and Chemotherapy. San Diego, CA: American Society
of Microbiology, 2002; 388.
18. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treat-
ment for less-common, emerging, or refractory fungal
infections. Clin Infect Dis 2003; 36: 1122–31.
19. Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria
boydii brain abscess successfully treated with voriconazole
and surgical drainage: case report and literature review of
central nervous system pseudallescheriasis. Clin Infect Dis
2000; 31: 673–7.
20. Poza G, Montoya J, Redondo C et al. Meningitis caused by
Pseudallescheria boydii treated with voriconazole. Clin Infect
Dis 2000; 30: 981–2.
21. Tan KKC, Wood N, Weil A. Multiple-dose pharmacoki-
netics of voriconazole in chronic hepatic impairment
[Abstract A-16]. In: Program and Abstracts of the 41st Inter-
science Conference on Antimicrobial Agents and Chemotherapy.
Chicago, IL: American Society of Microbiology, 2001; 1.
22. Ghahramani P, Purkins L, Kleinermans D et al. Effects of
rifampicin and rifabutin on the pharmacokinetics of vor-
iconazole [Abstract 844]. In: Program and Abstracts of the
40th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Toronto, Ont.: American Society of Micro-
biology, 2000: 23.
23. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of
voriconazole on the pharmacokinetics of cyclosporine in
renal transplant patients. Clin Pharmacol Ther 2002; 71: 226–
34.
24. Wood N, Tan K, Allan R et al. Effect of Voriconazole on
the pharmacokinetics of tacrolimus [Abstract A-20]. In:
Program and Abstracts of the 41st Interscience Conference on
Antimicrobial Agents and Chemotherapy. Chicago, IL:
American Society of Microbiology, 2001; 2.
25. Singh N, Zhang S, Gayowski T, Venkataramanan R. Vor-
iconazole inhibition of tacrolimus metabolism after liver
transplantation and in human liver microsomes [Abstract
A-21]. In: Program and Abstracts of the 41st Interscience
Conference on Antimicrobial Agents and Chemotherapy. Chi-
cago, IL: American Society of Microbiology, 2001; 2.
26. Purkins L, Wood N, Kleinermans D, Nichols D. Vorico-
nazole potentiates warfarin-induced prothrombin time
prolongation. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 24–9.
27. Ghahramani P, Purkins L, Kleinermans D et al. The
pharmacokinetics of voriconazole and its effect on
prednisolone disposition [Abstract 842]. In: Program and
Abstracts of the 40th Interscience Conference on Antimicrobial
Agents and Chemotherapy. Toronto, Ont.: American Society
of Microbiology, 2000: 23.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Vorico-
nazole does not affect the steady-state pharmacokinetics of
digoxin. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 45–50.
29. Wood N, Abel S, Fielding A et al. Voriconazole does
not affect the pharmacokinetics of mycophenolic acid
[Abstract A-24]. In: Program and Abstracts of the 41st Inter-
science Conference on Antimicrobial Agents and Chemotherapy.
Chicago, IL: American Society of Microbiology, 2001; 3.
30. Purkins L, Wood N, Ghahramani P et al. Coadministration
of voriconazole and phenytoin: pharmacokinetic inter-
action, safety, and toleration. Br J Clin Pharmacol 2003; 56;
(Suppl. 1): 37–44.
31. Wood N, Tan K, Purkins L et al. Effect of omeprazole on
the steady state pharmacokinetics of voriconazole. Br J
Clin Pharmacol 2003; 56 (suppl. 1): 56–61.
32. Wood N, Tan K, Allan R et al. Effect of voriconazole on the
pharmacokinetics of omeprazole [Abstract A-19]. In: Pro-
gram and Abstracts of the 41st Interscience Conference on
Antimicrobial Agents and Chemotherapy, Chicago, IL:
American Society of Microbiology, 2001; 2.
33. Purkins L, Wood N, Kleinermans D, Love ER. No clinically
signiﬁcant pharmacokinetic interactions between vorico-
nazole and indinavir in healthy volunteers. Br J Clin
Pharmacol 2003; 56 (Suppl. 1): 62–8.
34. Tomaszewski K, Nurbhai N, Baruch A. The overall clinical
safety of voriconazole [Abstract 123]. Presented at the
Tandem BMT Meetings, Orlando, FL, USA. Biol Blood Mar-
row Transplant 2002; 8: 95–6.
35. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses
Study Group multicenter trial of oral itraconazole therapy
for invasive aspergillosis. Am J Med 1994; 97: 135–44.
36. Caillot D, Bassaris H, McGeer A et al. Intravenous itrac-
onazole followed by oral itraconazole in the treatment of
invasive pulmonary aspergillosis in patients with hema-
tologic malignancies, chronic granulomatous disease, or
AIDS. Clin Infect Dis 2001; 33: e83–90.
37. Caillot D. Intravenous itraconazole followed by oral
itraconazole for the treatment of amphotericin-B-refractory
invasive pulmonary aspergillosis. Acta Haematol 2003; 109:
111–18.
Donnelly and De Pauw Voriconazole – a new therapeutic agent 117
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 1), 107–117
